Sermorelin vs HGH: Differences, Safety, Cost

Key takeaways

• Sermorelin is not a weaker HGH. It is a 29-amino-acid fragment of growth hormone-releasing hormone that makes your own pituitary release growth hormone, with feedback still capping the response. HGH (somatropin) is the hormone itself, and the dose sets the level.
• HGH has far more evidence and a stronger effect: in healthy older adults it moved about 2 kg from fat to lean mass, with no functional benefit and more swelling, joint pain, carpal tunnel and glucose problems. Sermorelin's adult evidence is a few trials of 10 to 19 people.
• The legal line is sharp. HGH may be distributed only for FDA-approved uses such as diagnosed GH deficiency; for anti-aging it is a federal felony. Sermorelin is a compounded prescription a clinician may write off-label.
• Cost: compounded sermorelin about $150 to $400 a month; growth hormone about $350 to more than $3,000 cash, or a copay with insurance when the diagnosis qualifies.

Sermorelin vs HGH comes down to one question: is your pituitary working? Sermorelin, a fragment of growth hormone-releasing hormone, asks a working pituitary to release more of its own growth hormone, within the limits feedback allows; it can be legally prescribed for an adult with symptoms and a low IGF-1, costs about $150 to $400 a month, and has small trials behind it. HGH (somatropin) replaces growth hormone directly, works without the pituitary, has much larger trials, and may legally be dispensed only for an FDA-approved diagnosis. Our HGH peptides vs HGH hub covers all the secretagogues, best HGH peptides ranks them, and the sermorelin profile has the full evidence.

Sermorelin vs HGH, side by side

Sermorelin prices are from our peptide therapy cost guide; the GH figure is one price tracker's September 2026 estimate, and your own quote depends on brand, dose and insurance.

How they compare on evidence

Growth hormone has the larger, clearer record. In a systematic review of 18 study populations, 220 healthy older adults (mean age 69) who received GH lost 2.1 kg of fat and gained 2.1 kg of lean mass compared with controls, with no change in weight or bone density, and were more likely to develop soft-tissue edema, joint pain, carpal tunnel syndrome and gynecomastia, and somewhat more likely to develop diabetes or impaired fasting glucose. The authors concluded GH cannot be recommended as an anti-aging therapy (Liu 2007). Those trials started at an average of 14 mcg/kg a day, about 1 mg for a 70 kg adult.

Sermorelin's record is small and mostly about hormones. At 1 mg twice a day for 14 days, it restored 24-hour GH and IGF-1 in ten men aged about 68 to the levels of men in their twenties, without changing fasting glucose; half that dose produced no significant change (Corpas 1992). At 2 mg once nightly for six weeks, in 11 men aged 64 to 76, it raised overnight GH but not IGF-1, improved two of six strength measures, and changed nothing in body composition, weight or lipids (Vittone 1997). The authors read that as a sign that single nightly doses are less effective than multiple daily ones.

The only direct comparison is in children. In children with GH deficiency, increases in height velocity with sermorelin, given as a continuous infusion or in three divided doses, were smaller than with once-daily somatropin; the approved once-daily sermorelin dose was never compared with somatropin directly (Prakash & Goa 1999). Nothing comparable exists in adults.

The practical gap is dose. Most telehealth programs prescribe 200 to 500 mcg of sermorelin a night, several times less than the 1 to 2 mg a day that moved hormone levels in the trials. The sermorelin dosage chart and the peptide calculator show the arithmetic for common vials.

Safety: what each one risks

Growth hormone's side effects are documented and dose-related. In one brand's adult-deficiency trials, during the six-month placebo-controlled phase, peripheral swelling affected 17.5% versus 5.1% on placebo, joint pain 17.3% versus 4.2%, peripheral edema 10.8% versus 2.6% and paresthesia 9.6% versus 1.9%, mostly early and often relieved by a lower dose. The label also warns that GH can unmask impaired glucose tolerance or diabetes, and it is contraindicated in active malignancy, active proliferative or severe non-proliferative diabetic retinopathy and acute critical illness (Genotropin label 2026).

Sermorelin's documented side effects are milder: injection-site pain and transient facial flushing were the most common in the pediatric program, and single and repeated doses were well tolerated (Prakash & Goa 1999). Its feedback-limited mechanism makes high-GH effects less likely at the doses clinics use. The caveat is that nobody has run a long-term safety study of sermorelin in healthy adults, so the theoretical risks of raising IGF-1, including in anyone with an active or recent cancer, apply to both. Our sermorelin side effects page has the detail.

Who should consider which

Consider growth hormone, through an endocrinologist, if you have pituitary or hypothalamic disease, pituitary surgery or radiation, a significant head injury, or GH deficiency from childhood, and a stimulation test confirms adult GH deficiency. The Endocrine Society requires that confirmation in most cases and notes that a normal IGF-1 does not exclude the diagnosis (Molitch 2011). In that setting sermorelin is the wrong tool: it needs the pituitary cells that are missing.

Consider sermorelin if you are an adult with symptoms and a documented low IGF-1, no pituitary disease, and a clinician who will measure IGF-1 and glucose before starting and at 8 to 12 weeks, and stop if nothing changes. Ask what dose they expect to move IGF-1.

Consider neither if you have an active cancer or a cancer history your oncologist has not reviewed, diabetic retinopathy, uncontrolled diabetes, a pregnancy, or an unevaluated pituitary or brain mass; if you are a tested athlete; or if your goal is anti-aging, where neither has evidence of benefit.

The legal line

The single biggest difference is not pharmacological. Under 21 U.S.C. 333(e), knowingly distributing human growth hormone, or possessing it with intent to distribute, for any use in humans other than treating a disease or recognized condition where that use has been authorized under the drug-approval law and ordered by a physician, is a felony punishable by up to five years in prison, or ten if the recipient is under 18. The statute defines human growth hormone as somatrem, somatropin or an analogue of either (21 U.S.C. 333(e)).

Two things follow. A physician's order alone is not enough: for growth hormone, unlike most drugs, off-label use is the offense, so a prescription for anti-aging or bodybuilding does not make it lawful. And sermorelin, an analogue of GHRH rather than of somatropin, sits outside that provision; it is regulated like any compounded drug, which is why a licensed pharmacy may fill it on an off-label prescription. The rest of the legal picture is in are peptides legal?.

Bottom line

HGH is the stronger, better-studied drug and the right one for confirmed growth hormone deficiency; for anything else it is a felony to distribute and, in healthy older adults, a poor trade of side effects for a body-composition change that did not improve function. Sermorelin is weaker, cheaper, feedback-limited and legal to prescribe, with small trials that show it raises growth hormone and, at adequate doses, IGF-1. If you are choosing between them without a diagnosis, the real choice is sermorelin with measured IGF-1, or nothing.

Frequently asked questions

+−Is sermorelin the same as HGH?

No. HGH is somatropin, a 191-amino-acid copy of growth hormone that you inject in place of your own. Sermorelin is a 29-amino-acid fragment of growth hormone-releasing hormone that tells your pituitary to release its own growth hormone. Because the pituitary still answers to feedback from IGF-1 and somatostatin, sermorelin's effect is capped and it needs a working pituitary; HGH sets the level directly. They also differ in law: HGH may be distributed only for FDA-approved uses, while sermorelin is a compounded prescription drug.

+−Is sermorelin safer than HGH?

Probably, at the doses people use, but it has never been tested head to head. Sermorelin's common side effects in its pediatric program were injection-site reactions and flushing, and its feedback-limited mechanism makes the fluid retention, joint pain and glucose problems of high GH levels less likely. HGH's side effects are well documented: in adult deficiency trials of one brand, swelling affected 17.5% versus 5.1% on placebo. The long-term safety of sermorelin in healthy adults has simply not been studied.

+−Is sermorelin as effective as HGH?

No, and nobody claims otherwise in the literature. In the one comparison we found, in children with GH deficiency, height gains on sermorelin given by infusion or in divided doses were smaller than on daily somatropin. In older men, 1 mg of sermorelin twice a day restored growth hormone and IGF-1 to young-adult levels over 14 days, but the outcome trials were tiny. Growth hormone produced about 2 kg of fat-to-lean change in healthy older adults; sermorelin has no equivalent result.

+−Is sermorelin cheaper than HGH?

Usually. Compounded sermorelin runs about $150 to $400 a month through telehealth in October 2026, often including the clinician. Brand growth hormone ranges from about $350 to more than $3,000 a month cash depending on brand and dose, although people with a confirmed deficiency and commercial insurance may pay $0 to $200 with copay assistance. Without a qualifying diagnosis, HGH has no legal price at all.

+−Can a doctor prescribe HGH for anti-aging?

No. Federal law, 21 U.S.C. 333(e), makes it a felony to distribute growth hormone for any use other than one FDA has authorized and a physician has ordered, with up to five years in prison, or ten if the patient is under 18. Off-label prescribing, legal for most drugs, is exactly what this statute forbids. Anti-aging, bodybuilding and athletic performance are not authorized uses.

+−Is sermorelin FDA approved?

It was. Sermorelin was approved as Geref for children with growth hormone deficiency and as a diagnostic test, and the brand was withdrawn in 2008 for commercial reasons, not safety. Because it was the active ingredient of an approved drug, state-licensed 503A pharmacies may still compound it on prescription. Compounded sermorelin is not itself an FDA-approved product, and adult wellness use was never part of the approval.

+−Can I switch from HGH to sermorelin?

It depends on why you are on HGH. If you have diagnosed GH deficiency from pituitary surgery, radiation or a tumor, sermorelin may do little, because it needs the pituitary cells that were lost; that decision belongs to your endocrinologist. If you were using growth hormone for anti-aging without a qualifying diagnosis, sermorelin is the legal, prescribable alternative, with a smaller and less predictable effect, and the way to judge it is a repeat IGF-1 at 8 to 12 weeks.

Sources

1. Regulatory21 U.S.C. 333(e): prohibited distribution of human growth hormone. Legal Information Institute, Cornell Law School (read October 10, 2026).
2. LabelPfizer. GENOTROPIN (somatropin) for injection: full prescribing information. DailyMed, version published August 2026. (Genotropin label 2026) (2026)
3. ReviewPrakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs 1999;12:139-57. (1999)
4. StudyCorpas E et al. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and IGF-I levels in old men. J Clin Endocrinol Metab 1992;75:530-5. (1992)
5. StudyVittone J et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism 1997;46:89-96. (1997)
6. ReviewLiu H et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 2007;146:104-15. (2007)
7. GuidelineMolitch ME et al. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96:1587-609. (2011)
8. SourceMedFinder. Somatropin: estimated insurance and cash pricing (last updated September 3, 2026). (MedFinder 2026) (2026)